Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NCNO vs GDRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GDRX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–5 Matrix Metrics)

GDRX Overall Winner 6-Pillar Tally: NCNO 2 – 4 GDRX Matrix Metrics: NCNO 5 – 4 GDRX

As of Nov 17, 2026, GoodRx Holdings, Inc. (GDRX) is the stronger overall head-to-head candidate over nCino, Inc. (NCNO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). NCNO carries a Unified Composite Score of 49.3/100 (HOLD) at $22.43 (22.2x Forward P/E, 8.2% operating margin), whereas GDRX carries 54.4/100 (HOLD) at $3.45 (10.0x Forward P/E, 11.4% operating margin).

  • Technical & Structure Timing Caution: NCNO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.2); meanwhile GDRX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NCNO vs GDRX
NCNO NASDAQ
nCino, Inc. Common Stock
Services-Prepackaged Software
$22.43
-1.51% 1D
Market Cap $2.4B
TTM Revenue $622M
Forward P/E 22.2x
Beta / 30D Vol 0.40β · 38% Vol
Unified Composite Score
49.3 / 100 HOLD
Tech 38.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 53
RSI-14: 53.2 · SMA20: $22.80 · SMA50: $21.19
GDRX NASDAQ Head-to-Head Winner
GoodRx Holdings, Inc. Class A Common Stock
Services-Computer Processing & Data Preparation
$3.45
-1.71% 1D
Market Cap $1.2B
TTM Revenue $785M
Forward P/E 10.0x
Beta / 30D Vol 1.22β · 47% Vol
Unified Composite Score
54.4 / 100 HOLD
Tech 49.0 Fund 60.0 Flow 74.0 Mom 56.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 48
RSI-14: 47.8 · SMA20: $3.55 · SMA50: $3.44

6-Pillar Scorecard Institutional Category Breakdown (NCNO 2 – 4 GDRX)

Columns: Metric · NCNO · GDRX
1. Valuation Multiples GDRX
Forward P/E 22.2x 10.0x
Trailing P/E 71.1x 71.2x
PEG Ratio N/M N/M
EV / Revenue 4.3x 1.9x
2. Growth & Scale NCNO
Revenue Growth (YoY) +8.2% -1.3%
Earnings Growth (YoY) +147.6% -44.5%
TTM Revenue (USD) $622M $785M
Market Cap $2.4B $1.2B
3. Profitability & Quality GDRX
Gross Margin 62.2% 90.8%
Operating Margin 8.2% 11.4%
Net Profit Margin 5.4% 2.1%
Return on Equity (ROE) 3.9% 2.5%
4. Balance Sheet & Cash Flow NCNO
Cash Generation (TTM) $132M $132M
Cash Flow Margin 21.2% 16.8%
Net Cash / Leverage $255M Net Debt (0.36x D/E) $243M Net Debt (0.83x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GDRX
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 55.7% (20th %ile) 66.5% (16th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat GDRX
OpEx & R&D Intensity 54.0% of Rev ($336M) 79.4% of Rev ($623M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NCNO (5) vs GDRX (4)
Institutional Metric NCNO GDRX Criterion Row Edge
Market Capitalization
Scale
$2.4B $1.2B Larger Scale NCNO
Trailing P/E Ratio
Valuation
71.1x 71.2x Lower Multiple Tie
Forward P/E Ratio
Valuation
22.2x 10.0x Lower Multiple GDRX
Revenue Growth (YoY)
Growth
+8.2% -1.3% Higher Growth NCNO
Operating Margin (TTM)
Profitability
8.2% 11.4% Higher Margin GDRX
Net Profit Margin
Profitability
5.4% 2.1% Higher Margin NCNO
Return on Equity (ROE)
Capital Efficiency
3.9% 2.5% Higher ROE NCNO
52-Week Range Position
Momentum
63% ($14–$28) 79% ($2–$4) Stronger Trend GDRX
Beta / 30D Volatility
Risk Regime
0.40β · 38% Vol 1.22β · 47% Vol Lower Realized Risk NCNO
Unified Institutional Score
Composite Signal
49.3 / 100 (HOLD) 54.4 / 100 (HOLD) Higher Composite GDRX
Trailing 12M Revenue (USD)
Operating Scale
$622M $785M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
62.2% 90.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.3x EV/Rev N/M PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$132M ($255M Net Debt (0.36x D/E)) $132M ($243M Net Debt (0.83x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NCNO +7.88 pp
NCNO: +10.25% · GDRX: +2.37%
3M Horizon NCNO +10.97 pp
NCNO: +8.43% · GDRX: -2.54%
6M Horizon NCNO +12.17 pp
NCNO: +49.07% · GDRX: +36.9%
1Y Horizon GDRX +28.25 pp
NCNO: -12.09% · GDRX: +16.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NCNO Revenue GDRX Revenue NCNO Op. Margin GDRX Op. Margin Margin Leader
FY2019 N/A $390M N/A 36.0% GDRX
FY2020 $140M $550M -20.4% -50.1% NCNO
FY2021 $200M $750M -20.9% 1.8% GDRX
FY2022 $270M $770M -26.1% 0.2% GDRX
FY2023 $410M $750M -23.0% -3.6% GDRX
FY2024 $480M $790M -8.3% 8.3% GDRX
FY2025 $540M $800M -3.4% 11.0% GDRX
FY2026 $590M N/A 0.6% N/A NCNO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NCNO CONSOLIDATION
52d in phase · OBV DISTRIBUTION
Current IV 55.7%
IV Percentile 20th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NCNO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GDRX BREAKOUT
118d in phase · OBV NEUTRAL
Current IV 66.5%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact GDRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NCNO Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $2.4B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($336M)
90D Engineering Disclosures 0 Published
GDRX Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.2B market capitalization and 11.4% operating margin.
OpEx & R&D Reinvestment 79.4% of Rev ($623M)
90D Engineering Disclosures 0 Published

Investor FAQ NCNO vs GDRX Key Questions & Quantitative Answers

As of Nov 17, 2026, GoodRx Holdings, Inc. (GDRX) is the stronger overall head-to-head candidate over nCino, Inc. (NCNO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). NCNO carries a Unified Composite Score of 49.3/100 (HOLD) at $22.43 (22.2x Forward P/E, 8.2% operating margin), whereas GDRX carries 54.4/100 (HOLD) at $3.45 (10.0x Forward P/E, 11.4% operating margin). Technical & Structure Timing Caution: NCNO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.2); meanwhile GDRX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NCNO leads the Growth & Scale pillar: NCNO posts +8.2% YoY revenue growth and +147.6% YoY earnings growth on $622M TTM revenue (62.2% gross margin, 8.2% operating margin), compared with GDRX at -1.3% YoY revenue growth and -44.5% YoY earnings growth on $785M TTM revenue (90.8% gross margin, 11.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), NCNO cumulative revenue shifted +321.4% while GDRX shifted +105.1%. In operating R&D and SG&A reinvestment, NCNO deploys 54.0% of Rev ($336M) (0 90-day corporate R&D disclosures) versus 79.4% of Rev ($623M) (0 disclosures) for GDRX.

GDRX screens cheaper on headline valuation multiples. NCNO trades at 22.2x Forward P/E, 71.1x Trailing P/E, N/M PEG, and 4.3x EV/Revenue (21.2% FCF margin), whereas GDRX trades at 10.0x Forward P/E, 71.2x Trailing P/E, N/M PEG, and 1.9x EV/Revenue (16.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NCNO (3.9% ROE) versus GDRX (2.5% ROE) capital efficiency.

In options market volatility and institutional positioning, NCNO carries 55.7% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.40β · 38% Vol realized risk). By comparison, GDRX carries 66.5% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.22β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.